<article id="efficacy_wAMD_gains" class="slide efficacy-chart tabbed" data-ag-name="Efficacy wAMD Gains">
  <div class="tab-title">wAMD</div>

  <h2 class="slide-title">EYLEA<sup class="reg">&reg;</sup> DEMONSTRATED GAINS <br>IN LETTERS OF VISION (2° ENDPOINT)<sup class="footnote-link">1</sup></h2>
  <div class="tabs">
    <ul>
      <li class="first" id="wamd-gains-active"><img src="content/img/chart-first-bg.png" /></li>
      <li class="last"><img src="content/img/chart-second-bg.png" /></li>
    </ul>
  </div>

  <div class="chart" id="wamd-gains-first">
    <div class="chart-desc">
      Change from baseline to 1 year in BCVA (as measured by ETDRS letter score)
    </div>
    <div class="chart-img"><img src="content_EN/img/charts_lg-wamd.png" /></div>
    <div class="chart-details">
      <span>Adapted from EYLEA<sup class="reg">&reg;</sup> Product Monograph.</span> <span>Least-squares mean: 0.26; 95% CI (-1.97, 2.49)</span>
    </div>
    <div class="further-details three-lines">
       Patients receiving EYLEA<sup class="reg">&reg;</sup> once every 2 months (after 3 initial monthly doses):
       <ul>
         <li>Demonstrated comparable gains in letters of vision vs. monthly ranibizumab</li>
         <li>Were given an average of 7.6 vs. 12.1 injections for ranibizumab</li>
       </ul>
              <span class="parallelogram"></span>
    </div>
  </div>

  <div class="chart" id="wamd-gains-last" style="display: none;">
    <div class="chart-desc">
      Change from baseline to 1 year in BCVA (as measured by ETDRS letter score)
    </div>
    <div class="chart-img"><img src="content_EN/img/charts_lg2-wamd.png" /></div>
    <div class="chart-details">
      <span>Adapted from EYLEA<sup class="reg">&reg;</sup> Product Monograph.</span> <span>Least-squares mean: -0.90; 95% CI (-3.06, 1.26)</span>
    </div>
    <div class="further-details three-lines">
       Patients receiving EYLEA<sup class="reg">&reg;</sup> once every 2 months (after 3 initial monthly doses):
       <ul>
         <li>Demonstrated comparable gains in letters of vision vs. monthly ranibizumab</li>
         <li>Were given an average of 7.7 vs. 12.7 injections for ranibizumab</li>
       </ul>
        <span class="parallelogram"></span>

    </div>
  </div>

  <div class="reveal-study-design"><span>+</span><span>Study Design</span></div>
  <div id="popup-text">
    <h3>STUDY DESIGN</h3>
    <p>
      <span class='bullet'>*</span>VIEW 1 was a randomized, multicentre, double-blind, active-controlled study in adult patients with wAMD. Patients were assigned in a 1:1:1:1 ratio to either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q8 following 3 initial monthly doses (n=303), EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 (n=304), EYLEA<sup class="reg">&reg;</sup> 0.5&nbsp;mg Q4 (n=304) or ranibizumab 0.5&nbsp;mg Q4 (n=306). This trial included doses that differ from the recommended dose of EYLEA<sup class="reg">&reg;</sup>. The recommended dose of EYLEA<sup class="reg">&reg;</sup> is 2&nbsp;mg (0.05&nbsp;mL, or 50 µL) administered by intravitreal injection monthly for 3 initial doses followed by one dose administered once every 2 months.
    </p>
    <p>
      <span class='bullet'>†</span>VIEW 2 was a randomized, multicentre, double-blind, active-controlled study in adult patients with wAMD. Patients were assigned in a 1:1:1:1 ratio to either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q8 following 3 initial monthly doses (n=313), EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 (n=313), EYLEA<sup class="reg">&reg;</sup> 0.5&nbsp;mg Q4 (n=311) or ranibizumab 0.5&nbsp;mg Q4 (n=303). This trial included doses that differ from the recommended dose of EYLEA<sup class="reg">&reg;</sup>. The recommended dose of EYLEA<sup class="reg">&reg;</sup> is 2&nbsp;mg (0.05&nbsp;mL, or 50 µL) administered by intravitreal injection monthly for 3 initial doses followed by one dose administered once every 2 months. 
    </p>
  </div>
</article>